Efficacy of Ritlecitinib in Patients With Alopecia Areata by Extent of Hair Loss at Baseline: Post Hoc Analysis of the Phase 3 Long-Term ALLEGRO-LT Study

The post hoc analysis of the ALLEGRO-LT study evaluated the efficacy of ritlecitinib in 447 de novo patients with alopecia areata (AA) and ≥25% hair loss. After 15 months of treatment, patients with less than 95% hair loss at baseline achieved median SALT scores of <2.4, indicating almost complete scalp hair regrowth. In contrast, patients with ≥95% hair loss at baseline showed more refractory disease, but over one-third achieved a clinically meaningful SALT response (SALT ≤20 and SALT ≤10) by Month 15. Overall, ritlecitinib demonstrated efficacy in patients with varying extents of hair loss, including those with extensive hair loss at baseline.